article · ACS Medicinal Chemistry Letters
Targeted therapeutics have gained prominence in combating non-small cell lung carcinoma (NSCLC) and opportunistic bacterial infections like <i>Staphylococcus aureus</i> (<i>S. aureus</i>). This study explores dual-acting marine-inspired spirooxindoles to limit NSCLC and opportunistic bacteria. Pharmacophoric motifs from antitumor and antibacterial marine products were merged into a new series of pyrazole-clubbed spirooxindoles via a stereoselective [3 + 2] cycloaddition reaction. MTT screening identified <b>4e</b>, <b>4i</b>, and <b>4p</b>-<b>4s</b> as potent cytotoxic agents, with <b>4p</b> showing exceptional activity (IC<sub>50</sub> = 0.042 μM) and tumor selectivity (SI = 58.28). <b>4p</b> exhibited antibacterial efficacy against <i>S. aureus</i> (MIC = 25 μg/mL). DNA damage studies using a terbium(III) chloride biosensor revealed <b>4p</b>'s ability to damage both calf thymus and <i>S. aureus</i> DNA at low concentrations. Docking simulations presumed that <b>4p</b> binds between DNA strands, while apoptosis studies indicated it induced G1/S phase cell cycle arrest and increased A549 apoptosis by 33.65%. These findings highlight <b>4p</b> as a promising lead for further studies.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1021/acsmedchemlett.5c00014
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.